"Buying Innovative" in the Healthcare Biotech Market in Europe
Identifying how institutions and purchasing authorities can facilitate competitive market demand for healthcare innovation in Europe.
The 2006 Aho Report on Creating an Innovative Europe stated that public procurement offers opportunities to drive innovation by creating innovation friendly markets, while at the same time improving the level of public services. The adoption of the new European legislative package for public procurement in February 2014 established a more efficient and flexible framework for the public procurement of goods, works and services across the Union.
Building on this perspective, the objective of this briefing paper is to describe how the sound use of public procurement can drive demand for and provision of innovative biological medicines. Ultimately it aims to identify how institutions and purchasing authorities can facilitate competitive market demand for healthcare innovation in Europe.
This paper proposes key steps to consider when purchasing biological medicines, looking at each stage of the procurement process. It builds on the examples collected in the 2015 EuropaBio White Paper on Public Procurement of Biological Medicines and includes additional evidence and best practices for purchasing authorities to use as needed and appropriate.
You can read it below on download the PDF.